Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer

Cancer

Volumn 122, Issue 1, 2016, Pages 78-83

  Mahal, Brandon A ^a   Aizer, Ayal A ^a   Efstathiou, Jason A ^b   Nguyen, Paul L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

aggressive disease; cancer outcome; Gleason score; prostate specific antigen; prostatic neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; PRIORITY JOURNAL; PROSTATE CANCER; CANCER REGISTRY; CANCER STAGING; COHORT ANALYSIS; DISEASE COURSE; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; REGRESSION ANALYSIS; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84941686454     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29691     Document Type: Article

References (18)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. D'Amico AV, Whittington R, Malkowicz SB, et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974.
3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer 2014. https://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed December 30, 2013.
4. Genega EM, Hutchinson B, Reuter VE, Gaudin PB,. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000; 13: 1186-1191.
5. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R,. Prostate cancer detection at low prostate specific antigen. J Urol. 2000; 163: 806-812.
6. Sokoloff MH, Yang XJ, Fumo M, Mhoon D, Brendler CB,. Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL. BJU Int. 2004; 93: 499-502.
7. D'Amico AV, Chen MH, Malkowicz SB, et al., Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/mL. Or less. J Urol. 2002; 167: 2025-2030.
8. Surveillance, Epidemiology, and End Results Program. SEER Cancer Statistics Review, 1975-2011. http://seer.cancer.gov/archive/csr/1975-2011/. Accessed August 2015.
9. Surveillance, Epidemiology, and End Results Program. SEER data, 1973-2011. http://seer.cancer.gov/data/access.html. Accessed August 2015.
10. Furlow B,. US National Cancer Institute investigates PSA coding errors. Lancet Oncol. 2015; 16: 614.
11. US Census Bureau. Census 2000 gateway. http://www.census.gov/main/www/cen2000.html. Accessed December 27, 2013.
12. US Department of Agriculture. Rural-urban continuum codes. http://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx. Accessed December 27, 2013.
13. Partin AW, Kattan MW, Subong EN, et al., Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277: 1445-1451.
14. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT,. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90: 766-771.
15. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR,. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007; 178: S14-S19.
16. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169: 517-523.
17. Berglund RK, Stephenson AJ, Cronin AM, et al., Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram. Urology. 2009; 73: 1098-1103.
18. McGuire BB, Helfand BT, Loeb S, et al., Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. BJU Int. 2012; 109: 1764-1769.